Royalty PharmaRPRX
About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees: 99
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
160% more call options, than puts
Call options by funds: $89M | Put options by funds: $34.2M
68% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 50
21% more capital invested
Capital invested by funds: $8.18B [Q4 2024] → $9.86B (+$1.68B) [Q1 2025]
7% more funds holding
Funds holding: 411 [Q4 2024] → 440 (+29) [Q1 2025]
7% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 146
0.92% more ownership
Funds ownership: 72.13% [Q4 2024] → 73.04% (+0.92%) [Q1 2025]
22% less funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 7 (-2) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Morgan Stanley Terence Flynn | 51%upside $54 | Overweight Maintained | 10 Jul 2025 |
Financial journalist opinion
Based on 3 articles about RPRX published over the past 30 days









